Modification of the terminal residue of apelin-13 antagonizes its hypotensive action
about
The hepatic apelin system: a new therapeutic target for liver diseaseElabela-apelin receptor signaling pathway is functional in mammalian systems.The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsRole of the Vasopressin/Apelin Balance and Potential Use of Metabolically Stable Apelin Analogs in Water Metabolism Disorders.Apelin treatment increases complete Fatty Acid oxidation, mitochondrial oxidative capacity, and biogenesis in muscle of insulin-resistant mice.Apelin promotes lymphangiogenesis and lymph node metastasis.Biased signaling favoring gi over β-arrestin promoted by an apelin fragment lacking the C-terminal phenylalanineApelin ameliorates TNF-α-induced reduction of glycogen synthesis in the hepatocytes through G protein-coupled receptor APJ.The role of apelin in the retina of diabetic rats.Reduction of arterial stiffness by exercise training is associated with increasing plasma apelin level in middle-aged and older adultsApelin and pulmonary hypertension.Apela Regulates Fluid Homeostasis by Binding to the APJ Receptor to Activate Gi Signaling.The apelin receptor: physiology, pathology, cell signalling, and ligand modulation of a peptide-activated class A GPCR.Effects of structural analogues of apelin-12 in acute myocardial infarction in rats.The effects of apelin on the electrical activity of hypothalamic magnocellular vasopressin and oxytocin neurons and somatodendritic Peptide release.The role of apelin in cardiovascular function and heart failure.Apelin-13 induces proliferation, migration, and collagen I mRNA expression in human RPE cells via PI3K/Akt and MEK/Erk signaling pathways.Headgroup-dependent membrane catalysis of apelin-receptor interactions is likely.Apelin gene transfer into the rostral ventrolateral medulla induces chronic blood pressure elevation in normotensive rats.Hypothalamic apelin/reactive oxygen species signaling controls hepatic glucose metabolism in the onset of diabetes.[Pyr1]Apelin-13(1-12) Is a Biologically Active ACE2 Metabolite of the Endogenous Cardiovascular Peptide [Pyr1]Apelin-13.Treatment-associated change in apelin concentration in patients with hypertension and its relationship with left ventricular diastolic function.Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production.Novel neurohormonal insights with therapeutic potential in chronic heart failure.Apelin, diabetes, and obesity.Update on apelin peptides as putative targets for cardiovascular drug discovery.The apelin peptides as putative targets in cardiovascular drug discovery and development.Adipokines, vascular wall, and cardiovascular disease: a focused overview of the role of adipokines in the pathophysiology of cardiovascular disease.Discovery of a novel small molecule agonist scaffold for the APJ receptor.Apelin-13 promotes cardiomyocyte hypertrophy via PI3K-Akt-ERK1/2-p70S6K and PI3K-induced autophagy.Vasopressin V1a receptors mediate the hypertensive effects of [Pyr1 ]apelin-13 in the rat rostral ventrolateral medulla.Protamine is an antagonist of apelin receptor, and its activity is reversed by heparin.Novel pathogenesis: regulation of apoptosis by Apelin/APJ system.Apelin effects on blood pressure and RAS in DOCA-salt-induced hypertensive rats.Plasma apelin and ADMA Levels in patients with essential hypertension.Apelin, an endogenous neuronal peptide, protects hippocampal neurons against excitotoxic injury.Associations between gene polymorphisms of the apelin-APJ system and the risk of hypertension.The role of apelin on the alleviative effect of Angiotensin receptor blocker in unilateral ureteral obstruction-induced renal fibrosis.By interacting with the C-terminal Phe of apelin, Phe255 and Trp259 in helix VI of the apelin receptor are critical for internalization.The differential effects of low and high doses of apelin through opioid receptors on the blood pressure of rats with renovascular hypertension.
P2860
Q28295197-DC499BEF-B293-47E9-B7F2-C6C3AB0B2023Q30032663-3DE9E6D7-B572-46D5-AC8B-B5C136B63D6BQ30486707-7D2074A9-823C-4817-8333-81786A1A75F0Q33742305-CCDD6DC5-765F-4F85-8CD9-A958F4F7756DQ34030044-A0F46E47-434C-4406-A368-CABB45DB4653Q34100995-47EDDF41-2E74-4305-B987-32A3E17DE777Q34107370-FE2B0075-7E00-4BE3-B142-5572283E13E7Q34600236-C9B45624-6C7B-432A-B4D5-216D7729AB01Q34854449-93FB5528-2348-422E-9715-BED8CEE8980BQ35137602-C7034176-3BBF-494D-A474-F0B892F69815Q35573931-928610B5-8068-4C3D-B047-7A1F63DA8B06Q35637503-D7F016A0-2F51-4AC7-A4D1-C52BD774972FQ36973488-FCF314BC-1F75-423F-B914-A1420731AD9DQ37102243-CB9776EA-F380-4A02-A0C1-B5182D48D563Q37161749-F3E72091-0107-4B7F-BD75-27656532BF21Q37201175-7FA37004-E320-4DD6-8DB0-D794FE68F9F7Q37288064-7B52AC9B-852E-4B75-BD33-BA2ED0052302Q37330205-DA40AC7F-00BF-421B-B13C-3552E76FE164Q37352447-470D8914-C3AE-481B-9BE9-69DE23444FEFQ37513099-E28432B6-0327-4635-89A7-0FD878A90115Q37670483-CC06D053-BEEE-4F0A-86D0-948567692DACQ37680306-1DB5B595-356D-4877-9692-6F0BBF1B1E81Q37695588-170BE917-6917-4EDB-B7DD-60B9BD2F4B6AQ37749836-F48A9B45-9015-4FD7-9DA8-7E6C79E7D3F7Q37897155-9FA80F86-5FDB-4781-ACC2-902322AFD269Q38014484-4ED0E4DB-D9DE-4159-94A9-D4D5B7E31371Q38088282-00F69B46-E3EF-44CB-A81A-BF7AF1BECB36Q38188874-D205DA88-7FD3-41AE-96B4-8383F0FEB078Q38760395-AB7F52AB-15E4-4EEE-A353-E5DFE3C3F09EQ38816685-939B6BEE-9CF2-4E6C-BF6C-6A223349FD1BQ38931663-E0E08EF5-C725-417F-A0B6-ED99E851F3B8Q38938652-03F8E157-EB1D-4153-80BB-317644175D31Q39240472-D5855A32-CF40-460D-BDC0-F879970329E5Q39471675-25C5324C-6AAD-4BEB-8D05-24AFBA422598Q39869419-0D6EA8AA-F7BD-478D-9BD0-96109CB63020Q40085897-DDD1698B-D907-4E47-AA12-C7C9AC703132Q40685047-3C4C690C-A0FD-4C28-B169-524ADE9D725EQ42158176-3D6DE783-358C-400C-B1E4-41EAE015C020Q42411890-A75794A8-B5A8-453B-B6C6-28BA4FC28E0BQ44343840-D285965A-2044-4E1B-8E9A-2D642E8287FD
P2860
Modification of the terminal residue of apelin-13 antagonizes its hypotensive action
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Modification of the terminal residue of apelin-13 antagonizes its hypotensive action
@ast
Modification of the terminal residue of apelin-13 antagonizes its hypotensive action
@en
Modification of the terminal residue of apelin-13 antagonizes its hypotensive action
@nl
type
label
Modification of the terminal residue of apelin-13 antagonizes its hypotensive action
@ast
Modification of the terminal residue of apelin-13 antagonizes its hypotensive action
@en
Modification of the terminal residue of apelin-13 antagonizes its hypotensive action
@nl
prefLabel
Modification of the terminal residue of apelin-13 antagonizes its hypotensive action
@ast
Modification of the terminal residue of apelin-13 antagonizes its hypotensive action
@en
Modification of the terminal residue of apelin-13 antagonizes its hypotensive action
@nl
P2093
P356
P1433
P1476
Modification of the terminal residue of apelin-13 antagonizes its hypotensive action
@en
P2093
Brian F O'Dowd
Dennis K Lee
Regina Cheng
Susan R George
Tuan Nguyen
Victor R Saldivia
P356
10.1210/EN.2004-0359
P407
P577
2005-01-01T00:00:00Z